Information was received from a healthcare professional (hcp) and a manufacturer¿s representative (rep) regarding the patient¿s implantable drug infusion device.The drugs being delivered were 12 mg/ml fentanyl at 1.799 mg/day (also reported as 2.9 mcg/day), 20 mg/ml bupivacaine at 2.998 mg/day (also reported as 5.8 mg/day), 1,000 mcg/ml clonidine at 149.9 mcg/day (also reported as 261 mcg/day), and 20 mg/ml morphine (unknown) at 3 mg/day (also reported as 5.8 mg/day).The reason for use was spinal pain.It was reported that the patient was somnolent on (b)(6) 2018 and "kept getting narcan." the hcp also noted that the patient was intubated and sedated all night and they cut the patient's doses in half.Troubleshooting/results performed during the call consisted of the caller inquiring if the patient could access the pump or adjust their dosing.Information was reviewed, including basic pump function and the use of a ptm if the pump is programmed for use with one.The patient was obtunded and had over-sedation characteristics in addition to symptoms previously reported.The hcp also reported that the patient has "other things going on." the patient is currently in the cardiac icu (intensive care unit) after cardiac surgery on (b)(6) 2018, unrelated to the pump.However, her icu doctor requested a 50% reduction of pump rate to manage her pain ¿the way they normally do it.¿ environmental/external/patient factors that may have led or contributed to the issue included the patient was admitted after cardiac surgery and no details were reported.Interventions/actions that were taken to resolve the issue included a rate reduction of 50%.The issue was resolved at the time of this report, and the patient status was listed as ¿alive - no injury.¿on (b)(6) 2018 the doctor requested additional 25% reduction of infusion rate.The patient¿s daughter stated she would prefer the pump be removed.The hcp has no further information for the manufacturer.There were no further complications reported/anticipated.
|